Carboplatin/Nedaplatin
Small molecule
Carboplatin/Nedaplatin is one of 46 small molecule programs targeting Esophageal Carcinoma. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Esophageal Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Eloxatin
TevaPhase 3
Taxotere
AAvyxa
Approved
Adrucil
EElorac, Inc.
Approved
Lenvima
EisaiPhase 3
Tecentriq
RochePhase 3
Lobaplatin
SSun Yat-sen University
Approved
Tuoyi
SSun Yat-sen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Esophageal Carcinoma1 trial
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Unknown status·—·Phase 1/2·NCT05777707·89 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carboplatin/Nedaplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]